Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis.
body composition
inflammation
nutrition–clinical
pancreatic cancer
postoperative complications
Journal
Frontiers in nutrition
ISSN: 2296-861X
Titre abrégé: Front Nutr
Pays: Switzerland
ID NLM: 101642264
Informations de publication
Date de publication:
2023
2023
Historique:
received:
09
10
2022
accepted:
23
01
2023
entrez:
2
3
2023
pubmed:
3
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Body composition parameters and immunonutritional indexes provide useful information on the nutritional and inflammatory status of patients. We sought to investigate whether they predict the postoperative outcome in patients with pancreatic cancer (PC) who received neoadjuvant therapy (NAT) and then pancreaticoduodenectomy. Data from locally advanced PC patients who underwent NAT followed by pancreaticoduodenectomy between January 2012 and December 2019 in four high-volume institutions were collected retrospectively. Only patients with two available CT scans (before and after NAT) and immunonutritional indexes (before surgery) available were included. Body composition was assessed and immunonutritional indexes collected were: VAT, SAT, SMI, SMA, PLR, NLR, LMR, and PNI. The postoperative outcomes evaluated were overall morbidity (any complication occurring), major complications (Clavien-Dindo ≥ 3), and length of stay. One hundred twenty-one patients met the inclusion criteria and constituted the study population. The median age at the diagnosis was 64 years (IQR16), and the median BMI was 24 kg/m Body composition changes during NAT are associated with surgical outcome in PC patients who receive pancreaticoduodenectomy after NAT. An increase in SMI during NAT should be favored to ameliorate the postoperative outcome. Immunonutritional indexes did not show to be capable of predicting the surgical outcome.
Sections du résumé
Background and aims
UNASSIGNED
Body composition parameters and immunonutritional indexes provide useful information on the nutritional and inflammatory status of patients. We sought to investigate whether they predict the postoperative outcome in patients with pancreatic cancer (PC) who received neoadjuvant therapy (NAT) and then pancreaticoduodenectomy.
Methods
UNASSIGNED
Data from locally advanced PC patients who underwent NAT followed by pancreaticoduodenectomy between January 2012 and December 2019 in four high-volume institutions were collected retrospectively. Only patients with two available CT scans (before and after NAT) and immunonutritional indexes (before surgery) available were included. Body composition was assessed and immunonutritional indexes collected were: VAT, SAT, SMI, SMA, PLR, NLR, LMR, and PNI. The postoperative outcomes evaluated were overall morbidity (any complication occurring), major complications (Clavien-Dindo ≥ 3), and length of stay.
Results
UNASSIGNED
One hundred twenty-one patients met the inclusion criteria and constituted the study population. The median age at the diagnosis was 64 years (IQR16), and the median BMI was 24 kg/m
Conclusion
UNASSIGNED
Body composition changes during NAT are associated with surgical outcome in PC patients who receive pancreaticoduodenectomy after NAT. An increase in SMI during NAT should be favored to ameliorate the postoperative outcome. Immunonutritional indexes did not show to be capable of predicting the surgical outcome.
Identifiants
pubmed: 36860690
doi: 10.3389/fnut.2023.1065294
pmc: PMC9968808
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1065294Commentaires et corrections
Type : ErratumIn
Informations de copyright
Copyright © 2023 Paiella, Azzolina, Trestini, Malleo, Nappo, Ricci, Ingaldi, Vacca, De Pastena, Secchettin, Zamboni, Maggino, Corciulo, Sandini, Cereda, Capretti, Casadei, Bassi, Mansueto, Gregori, Milella, Zerbi, Gianotti and Salvia.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
World J Clin Cases. 2019 Jan 6;7(1):28-38
pubmed: 30637250
Appl Physiol Nutr Metab. 2008 Oct;33(5):997-1006
pubmed: 18923576
BMC Med Imaging. 2019 Feb 11;19(1):15
pubmed: 30744586
BMC Res Notes. 2021 Jul 15;14(1):272
pubmed: 34266478
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg Oncol. 2015 Jul;22(7):2416-23
pubmed: 25519927
World J Gastrointest Surg. 2021 Sep 27;13(9):885-903
pubmed: 34621468
Medicine (Baltimore). 2018 Feb;97(8):e9616
pubmed: 29465553
Pancreatology. 2018 Dec;18(8):996-1004
pubmed: 30287167
Clin Nutr ESPEN. 2021 Aug;44:85-95
pubmed: 34330517
J Bone Metab. 2013 May;20(1):1-10
pubmed: 24524049
Br J Nutr. 2021 May 28;125(10):1140-1147
pubmed: 32883372
Surgery. 2017 Oct;162(4):792-801
pubmed: 28676333
Dig Dis Sci. 2017 Jun;62(6):1666-1675
pubmed: 28341868
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
BMC Surg. 2020 Apr 15;20(1):72
pubmed: 32293409
J Natl Compr Canc Netw. 2019 Mar 1;17(3):202-210
pubmed: 30865919
Ann Pancreat Cancer. 2019 Mar;2:
pubmed: 33554109
J Appl Physiol (1985). 2003 Oct;95(4):1717-27
pubmed: 12970377
Nutrients. 2021 Oct 07;13(10):
pubmed: 34684523
J Clin Med. 2022 Jan 26;11(3):
pubmed: 35160076
JAMA Surg. 2018 Sep 1;153(9):809-815
pubmed: 29801062
Eur J Clin Nutr. 2015 Oct;69(10):1079-86
pubmed: 25782424
Pancreas. 2018 Aug;47(7):793-799
pubmed: 29985846
J Clin Oncol. 2013 Apr 20;31(12):1539-47
pubmed: 23530101
HPB (Oxford). 2018 May;20(5):379-384
pubmed: 29336893
J Appl Physiol (1985). 2004 Dec;97(6):2333-8
pubmed: 15310748
Pancreatology. 2019 Sep;19(6):850-857
pubmed: 31362865
Surgery. 2016 Oct;160(4):987-996
pubmed: 27545992
Cancers (Basel). 2019 Sep 04;11(9):
pubmed: 31487957
Clin Nutr. 2012 Dec;31(6):817-30
pubmed: 23079762
Clin Chim Acta. 2018 Jun;481:142-146
pubmed: 29544747
Lancet Oncol. 2013 Oct;14(11):e476-e485
pubmed: 24079875
Ann Surg Oncol. 2020 Dec;27(13):5325-5334
pubmed: 32388740
J Clin Med. 2021 Jul 07;10(14):
pubmed: 34300199
Proc Nutr Soc. 2016 May;75(2):188-98
pubmed: 26743210
Clin Cancer Res. 2009 Nov 15;15(22):6973-9
pubmed: 19887488
World Health Organ Tech Rep Ser. 2000;894:i-xii, 1-253
pubmed: 11234459
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Nat Rev Clin Oncol. 2019 Jan;16(1):11-26
pubmed: 30341417
HPB (Oxford). 2019 Dec;21(12):1603-1612
pubmed: 31266698
Surgery. 2018 Nov;164(5):1035-1048
pubmed: 30029989
Cancers (Basel). 2019 May 23;11(5):
pubmed: 31126040